BioWorld - Tuesday, May 19, 2026
Breaking News: Bundibugyo is harsh reminder of need for broad vaccine strategiesBreaking News: Bundibugyo is harsh reminder of need for broad vaccine strategiesBreaking News: Bundibugyo is harsh reminder of need for broad vaccine strategies

BioWorld Science, Endocrine/metabolic
BioWorld Science, Endocrine/metabolic RSS Feed RSS

Neurons
Endocrine/Metabolic

MYT-109, a promising treatment for Leigh syndrome

Nov. 29, 2022
Leigh syndrome is a rare neurometabolic disorder that causes the CNS to degenerate. Investigators from the University of California, Davis, and Myto Therapeutics Inc. noted that the NDUFS4-knockout (KO) mouse is a well-characterized model for this disease and shared results on the effects of monomethyl fumarate prodrug MYT-109 in this murine model.
Read More
3D illustration of liver and photomicrograph showing triglyceride fat accumulated in liver cells.
Endocrine/Metabolic

LXR inverse agonist TLC-2716 reduces lipogenesis in preclinical models

Nov. 23, 2022
The liver X receptor (LXR) is a nuclear hormone receptor that is one of the most important regulators of cholesterol homeostasis and plays a key role in triglyceride (TG) regulation. Researchers from Orsobio Inc. and Phenex Pharmaceuticals AG have presented preclinical data on TLC-2716, a potent, small-molecule LXR inverse agonist for the treatment of lipid disorders.
Read More
Endocrine/Metabolic

TLC-6740 demonstrates multiple metabolic benefits in vivo

Nov. 22, 2022
Scientists from Orsobio Inc. and affiliated organizations have described preclinical data for the novel liver-targeted mitochondrial protonophore TLC-6740, being developed for the treatment of metabolic disease. In vitro, mild mitochondrial uncoupling caused by TLC-6740 had pleotropic metabolic benefits in multiple cell lines. TLC-6740 increased mitochondrial potential, oxygen consumption rate and tricarboxylic acid (TCA) cycle flux, and it also inhibited de novo lipogenesis with EC50 values of 6.9 µM.
Read More
Endocrine/Metabolic

Gilead Sciences describes new GLP-1R agonists

Nov. 18, 2022
Gilead Sciences Inc. has synthesized carboxy-benzimidazoles acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of arthritis, diabetes, eating disorders, macular degeneration, myocardial infarction, nonalcoholic steatohepatitis, sleep apnea and Parkinson's disease, among others.
Read More
Mitochondria long way from the nucleus and in need of closer sources of proteins
Neurology/Psychiatric

Neuroscience 2022: ‘Strawberries’, ‘cabbages,’ fats in neuronal mitochondria

Nov. 15, 2022
By Mar de Miguel
Neurons are specialized cells with a high metabolic demand to fulfill their function, survive or keep a healthy half-life. In this sense, the anabolism and catabolism of proteins and lipids could be associated to different neurodegenerative diseases. At the 2022 annual meeting of the Society for Neuroscience, scientists reported the latest discoveries on neuron metabolic needs at a session on 'Powering Thoughts: The Regulation of Neuronal Energy Metabolism and Mitochondria.'
Read More
Cancer research illustration
Cancer

From mouse to man, UBR2 is target in cancer cachexia

Nov. 14, 2022
By W. Todd Penberthy
Investigators working at University of Texas Health Science Center, Houston, have discovered that the ubiquitin ligase UBR2 is up-regulated and sufficient for targeting the myosin heavy chain protein for the degradation characteristic of cancer cachexia. UBR2 knockout or pharmacological inhibition could prevent cachexia in mice. Confirmatory observations were noted in cancer cachexia patient-derived tissues.
Read More